AbCellera Results Presentation Deck

FINANCIALS Q2 2022 BUSINESS UPDATE COPYRIGHT © ABCELLERA 12 6 molecules in the clinic. MOLECULE bamlanivimab (LY-CoV555) bebtelovimab (LY-CoV1404) NBL-012 NBL-015 undisclosed IVX-01 STAGE Marketed, Emergency Use Authorization (EUA) Marketed, Emergency Use Authorization (EUA) Phase 1 completed IND/CTA authorized IND/CTA authorized Clinical field study PARTNER Lilly Lilly NovaRock BOTHERAPEUTICS NovaRock BOTHERAPEUTICS undisclosed Invetx™ THERAPEUTIC AREA ● • ● ● ● ● ● ● infectious disease - COVID-19 infectious disease - COVID-19 dermatology gastrointestinal disease immunology oncology undisclosed animal health PROGRAM TYPE AbCellera Discovery Partnership Trianni License AbCellera Discovery Partnership As of June 30, 2022

View entire presentation